Synthesis of adansonia digitata nanoparticles

Abstract

A method of preparing Adansonia digitata nanoparticles includes dissolving Adansonia digitata plant powder in an organic solvent to form a solution; spraying the solution in boiling water while applying ultrasonic energy to form a mixture; and stirring the mixture for at least about 15 minutes at a speed of about 200-800 rpm to obtain the Adansonia digitata nanoparticles.

Claims

1. A method of synthesizing Adansonia digitata nanoparticles, comprising: dissolving Adansonia digitata plant powder in an organic solvent selected from the group consisting of at least one of methanol, ethanol, dichloromethane, and chloroform to form a solution; adding about 1 ml to about 4 ml of the solution to about 50 ml to about 100 ml of boiling water under ultrasonic conditions to form a mixture; and; stirring the mixture at a speed of about 200 rpm to about 800 rpm to obtain Adansonia digitata nanoparticles, wherein the ultrasonic conditions include sonication for about 10 minutes to about 20 minutes with an ultrasonic power of 100 W and a frequency of 30 kHz prior to being stirred, and wherein the Adansonia digitata nanoparticles have a mean diameter in the range of from about 50 nm to about 300 nm.

2. The method of synthesizing Adansonia digitata nanoparticles according to claim 1, further comprising isolating and drying the Adansonia digitata nanoparticles to obtain dried Adansonia digitata nanoparticle powder.

3. The method of synthesizing Adansonia digitata nanoparticles according to claim 1, wherein the Adansonia digitata plant powder is derived from the fruit pulp of Adansonia digitata.

4. The method of preparing Adansonia digitata nanoparticles according to claim 1, wherein the solution is added to the boiling water by spraying the solution dropwise into the boiling water at a rate of about 0.2 ml/minute in about 5 minutes.

5. The method of synthesizing Adansonia digitata nanoparticles according to claim 1, wherein the Adansonia digitata nanoparticles have spherical, spheroidal, elongated, spherical, rod-shaped, and/or faceted shapes.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIGS. 1A-1C show transmission electron microscopy (TEM) images of Adansonia digitata nanoparticles prepared according to Example 1.

(2) FIGS. 2A-2E show transmission electron microscopy (TEM) images of encapsulated Adansonia digitata nanoparticles prepared according to Example 2.

(3) FIG. 3 shows a graph of Zeta sizer for measuring the average particle size of the Adansonia digitata nanoparticles prepared according to Example 1.

(4) FIG. 4 shows a graph of Zeta sizer for measuring the average particle size of the encapsulated Adansonia digitata nanoparticles prepared according to the method in Example 2.

(5) Similar reference characters denote corresponding features consistently throughout the attached drawings.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

(6) A method of preparing Adansonia digitata nanoparticles includes dissolving Adansonia digitata plant powder, e.g., a powder formed from Adansonia digitata fruit pulp, seeds, leaves, flowers, roots, and/or bark, in an organic solvent to form a solution; adding the solution to boiling water under ultrasonic conditions to form a mixture; and stirring the mixture at room temperature for about ten minutes and a speed of about 200 rpm to about 800 rpm to obtain Adansonia digitata nanoparticles. Ultrasonic conditions can include applying ultrasonic energy of about 100 W at a frequency of about 30-60 kHz, e.g., about 30 kHz. Ultrasonication may be performed using an ultrasonic bath or an ultrasonic probe. The mixture can be sonicated for about 10 minutes to about 20 minutes prior to stirring. The organic solvent can be at least one of methanol, ethanol, dichloromethane, and chloroform. The solution can be sprayed into the boiling water dropwise with a flow rate of 0.2 mL/min for about five minutes. For example, about 3 mL of the solution can be added to about 100 mL of the boiling water.

(7) The Adansonia digitata nanoparticles prepared according to the inventive method can possess a mean diameter in the range of from about 50 nm to about 300 nm, e.g., about 230 nm. The Adansonia digitata nanoparticles can have spherical, spheroidal, elongated spherical, rod-shaped, and/or faceted shapes.

(8) A method of synthesizing carrier encapsulated Adansonia digitata nanoparticles includes dissolving Adansonia digitata, e.g., Adansonia digitata nanoparticle powder, and an appropriate amount of a carrier in an organic solvent to form an internal organic phase solution; adding the internal organic phase solution into an external aqueous solution to form a mixture; and homogenizing the mixture to obtain Adansonia digitata nanoparticles encapsulated with a carrier. The carrier can be Gum arabic. The organic solvent can include at least one of methanol, ethanol, dichloromethane and chloroform. The external aqueous solution can include water and polyvinyl alcohol. A ratio of Adansonia digitata:Gum arabic:PVA can be 1:5:3; w/w/w. The mixture can be homogenized at a speed of about 22,000 rpm for about 25 minutes to form carrier encapsulated Adansonia digitata nanoparticles. The encapsulated Adansonia digitata nanoparticles isolated from the ethanol and dried. The resulting nanoparticle powder can have an average size of about 90 nm to about 100 nm, e.g., 93 nm.

(9) Gum arabic, also known as acacia gum, is a natural gum including the hardened sap of various species of the acacia tree that grow in semi-arid land across sub-Saharan Africa. It is a complex heteropolysaccharide with a highly ramified structure, and the main chain is formed of d-galactopyranose units joined by β-d glycosidic bonds. This gum is widely used for encapsulating material, e.g., microencapsulation, by spray drying, mainly because of its emulsifying capacity and low viscosity in aqueous solution.

(10) An effective amount of the Adansonia digitata nanoparticles or encapsulated Adansonia digitata nanoparticles can be administered to a patient in need thereof for treating and/or preventing cancer. The patient can be human or animal. The cancer can be, for example, colon cancer or breast cancer.

(11) The present technology, thus generally described, will be understood more readily by reference to the following examples, which is provided by way of illustration and is not intended to limit the scope of the present technology.

Example 1

Synthesis of Adansonia digitata Nanoparticles in Methanol

(12) For the formation of Adansonia digitata nanoparticles, (200 mg) of Adansonia digitata fruit powder was taken in methanol (30 mL), and 3 mL of this solution was sprayed into boiling water (100 mL) dropwise with a flow rate of 0.2 mL/min in 5 min under ultrasonic conditions, with an ultrasonic power of 100 W and a frequency of 30 kHz. After sonication for 30 min, the contents were stirred at 200-800 rpm at room temperature for about 10 min, and then dried, to obtain Adansonia digitata nanoparticles beige powder with a particle size of 230.2 nm. FIGS. 1A-C show transmission electron microscopy (TEM) (JEM-1011, JEOL, Japan) images of Adansonia digitata nanoparticles obtained from the method of Example 1. FIG. 3 shows a graph of Zeta sizer (ZEN 3600, MALVERN, United Kingdom) for measuring the average particle size of the Adansonia digitata nanoparticles.

Example 2

Synthesis of Encapsulated Adansonia digitata Nanoparticles

(13) The nano precipitation technique (Bilati et al., 2005; Zili et al., 2005) was used for the formation of a nanoparticle encapsulation system with weight ratio Adansonia digitata:gum arabic:PVA (1:5:3; w/w/w). An amount of 100 mg of Adansonia digitata and an appropriate amount of gum arabic was dissolved in 50 ml of ethanol to form an internal organic phase solution. The internal organic phase solution was quickly injected into 130 ml external aqueous solution containing the appropriate amount of PVA, and then the solution was homogenized at 22,000 rpm for 25 minutes to form encapsulated Adansonia digitata nanoparticles. The ethanol was completely removed, dried, and the nanoparticles powder (93.73 nm in size) was collected. FIGS. 2A-2E show transmission electron microscopy (TEM) (TEM) (JEM-1011, JEOL, Japan) images of the Adansonia digitata nanoparticles encapsulated gum Arabic. FIG. 4 shows a graph of Zeta sizer (ZEN 3600, MALVERN, United Kingdom) for measuring the average particle size of the encapsulated Adansonia digitata nanoparticles.

Example 3

Antimicrobial Activity Evaluation

(14) The antimicrobial effect of the Adansonia digitata nanoparticles was evaluated against different gram positive and gram negative bacteria as well as fungi. Results of the antimicrobial effects are provided in Table 1. The test was done using the diffusion agar technique and the well diameter was 6.0 mm (100 μl was tested). The mean zone of inhibition in mm±Standard deviation beyond well diameter (6 mm) produced on a range of environmental and clinically pathogenic microorganisms.

(15) TABLE-US-00001 TABLE 1 Sample GON Tested GON GON Encapsulated microorganisms .sup.1Extract .sup.2NPs .sup.3NPs Standard FUNGI 16.0 ± 1.0 22.0 ± 1.0 22.0 ± 1.0 Amphoter- Aspergillus icin B fumigatus 21.7 ± 1.5 (RCMB 02567) Gram Positive Bacteria: Streptococcus 18.0 ± 2.0 20.3 ± 1.5 21.3 ± 1.5 Ampicillin pneumoniae 21.0 ± 1.0 (RCMB 010011) Bacillis subtilis 20.3 ± 1.2 24.0 ± 1.0 25.3 ± 1.2 31.3 ± 1.5 (RCMB 010068) Gram Negative Bacteria: Escherichia coli 17.7 ± 1.5 24.0 ± 2.0  24.7 ± 0.58 Gentamicin (RCMB 010054)  20.3 ± 0.58 .sup.1GON Extract Adansonia digitata extract .sup.2GON NPs = Adansonia digitata nanoparticles. .sup.3GON = Encapsulated Adansonia digitata nanoparticles.

Example 5

Cytotoxicity Evaluation

(16) The potential cytotoxic effect of the Adansonia digitata extract and synthesized Adansonia digitata nanoparticles was evaluated against two cell lines, namely the human Breast carcinoma cell line MCF7 and the human colon carcinoma cells HCT-116. The results achieved using Adansonia digitata extract are provided in Table 2. As shown in Table 2, Adansonia digitata extract demonstrated weak inhibitory activity against colon carcinoma cells. Under these experimental conditions, the value of IC.sub.50=>100 μl. The results achieved using encapsulated Adansonia digitata nanoparticles are provided in Tables 4 and 6.

(17) TABLE-US-00002 TABLE 2 Percentage of Inhibition Using Adansonia digitata Extract Standard Sample Viability % (3 Replicates) Inhibition Deviation conc. (μl) 1.sup.st 2.sup.nd 3.sup.rd Mean % (±) 100 64.93 67.14 69.26 67.11 32.89 2.17 50 82.56 85.23 81.41 83.07 16.93 1.96 25 91.87 94.06 90.37 92.10 7.90 1.86 12.5 98.04 99.21 96.76 98.00 2.00 1.23 6.25 100 100 100 100.00 0.00 0.00 3.125 100 100 100 100.00 0.00 0.00 0 100 100 100 100 0.00

(18) The results achieved using Adansonia digitata nanoparticles are provided in Tables 3 and 4. Table 3 shows the inhibitory activity against colon carcinoma cells. Under these experimental conditions, the value of IC.sub.50=73.6 μl.

(19) TABLE-US-00003 TABLE 3 Standard Sample Viability % (3 Replicates) Inhibition Deviation conc. (μl) 1.sup.st 2.sup.nd 3.sup.rd Mean % (±) 100 23.84 29.13 31.48 28.15 71.85 3.91 50 67.23 71.45 69.74 69.47 30.53 2.12 25 89.15 87.48 90.32 88.98 11.02 1.43 12.5 94.27 96.39 97.46 96.04 3.96 1.62 6.25 98.79 99.14 100 99.31 0.69 0.62 3.125 100 100 100 100.00 0.00 0.00 0 100 100 100 100 0.00

(20) Table 4 shows the inhibitory activity against breast carcinoma cells. Under these conditions, the value of IC.sub.50=64.7 μl.

(21) TABLE-US-00004 TABLE 4 Standard Sample Viability % (3 Replicates) Inhibition Deviation conc. (μl) 1.sup.st 2.sup.nd 3.sup.rd Mean % (±) 100 26.14 34.26 32.79 31.06 68.94 4.33 50 54.47 61.85 57.43 57.92 42.08 3.71 25 81.92 79.04 76.26 79.07 20.93 2.83 12.5 92.78 87.19 85.38 88.45 11.55 3.86 6.25 98.54 96.27 94.36 96.39 3.61 2.09 3.125 100 98.74 97.21 98.65 1.35 1.40 100 26.14 34.26 32.79 31.06 68.94 4.33

(22) The results achieved using encapsulated Adansonia digitata nanoparticles are provided in Tables 5 and 6. Table 5 shows the inhibitory activity against colon carcinoma cells. Under these experimental conditions, the value of IC.sub.50=34.1 μl.

(23) TABLE-US-00005 TABLE 5 Standard Sample Viability % (3 Replicates) Inhibition Deviation conc. (μl) 1.sup.st 2.sup.nd 3.sup.rd Mean % (±) 100 17.52 20.43 18.67 18.87 81.13 1.47 50 30.64 34.16 32.72 32.51 67.49 1.77 25 54.98 63.25 61.59 59.94 40.06 4.37 12.5 69.75 78.14 84.63 77.51 22.49 7.46 6.25 87.12 90.63 91.48 89.74 10.26 2.31 3.125 94.23 98.26 97.18 96.56 3.44 2.09 0 100 100 100 100 0.00

(24) Table 6 shows the inhibitory activity against Breast carcinoma cells. Under these experimental conditions, the value of IC.sub.50=18.3 μl.

(25) TABLE-US-00006 TABLE 6 Standard Sample Viability % (3 Replicates) Inhibition Deviation conc. (μl) 1.sup.st 2.sup.nd 3.sup.rd Mean % (±) 100 16.43 14.95 13.71 15.03 84.97 1.36 50 21.96 23.62 26.48 24.02 75.98 2.29 25 32.78 31.53 35.26 33.19 66.81 1.90 12.5 64.39 67.29 61.87 64.52 35.48 2.71 6.25 80.62 81.74 78.14 80.17 19.83 1.84 3.125 91.78 90.53 89.75 90.69 9.31 1.02 0 100 100 100 100 0.00

(26) It is to be understood that the present invention is not limited to the embodiments described above but encompasses any and all embodiments within the scope of the following claims.